Powered by: Motilal Oswal
01-01-1970 12:00 AM | Source: Accord Fintech
Lupin soars on launching Formoterol Fumarate Inhalation Solution
News By Tags | #196 #642 #572

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

Lupin is currently trading at Rs. 762.50, up by 11.65 points or 1.55% from its previous closing of Rs. 750.85 on the BSE.

The scrip opened at Rs. 750.85 and has touched a high and low of Rs. 765.00 and Rs. 747.45 respectively. So far 29364 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 972.50 on 14-Dec-2021 and a 52 week low of Rs. 583.05 on 25-May-2022.

Last one week high and low of the scrip stood at Rs. 765.00 and Rs. 709.60 respectively. The current market cap of the company is Rs. 34655.28 crore.

The promoters holding in the company stood at 47.11%, while Institutions and Non-Institutions held 41.44% and 11.45% respectively.

Lupin has launched Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P. Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of $268 million in the U.S. (IQVIA MAT September 2022).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.